This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What Analyst Projections for Key Metrics Reveal About Illumina (ILMN) Q3 Earnings
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Illumina (ILMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Should iShares S&P Mid-Cap 400 Value ETF (IJJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJJ
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Direxion NASDAQ-100 Equal Weighted Index Shares (QQQE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QQQE
Illumina's Q3 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?
by Moumi Mondal
In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing customer activity on NovaSeq X.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should Vanguard S&P Mid-Cap 400 ETF (IVOO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVOO
ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold?
by Moumi Mondal
Reaching a new one-year high, Illumina remains in investors' sight owing to its strong strategic execution and positive growth outlook.
MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests
by Zacks Equity Research
Myriad Genetics and Ultima Genomics to explore the latter's sequencing platform for advanced clinical tests in oncology and reproductive genomics.
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
by Zacks Equity Research
OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.
EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening
by Zacks Equity Research
Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.
Here's Why Illumina (ILMN) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should SPDR S&P 400 Mid Cap Value ETF (MDYV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MDYV
Should SPDR S&P MidCap 400 ETF (MDY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MDY
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU
by Zacks Equity Research
APLS stock falls as the CHMP confirms its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat GA in the EU.
Longboard Stock Soars on FDA Designations for Epilepsy Drug
by Zacks Equity Research
The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
by Zacks Equity Research
With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
by Zacks Equity Research
The FDA issues a complete response letter to Vanda's new drug application for tradipitant for treating symptoms in gastroparesis.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
by Zacks Equity Research
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.
EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies
by Zacks Equity Research
Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients.
APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA
by Zacks Equity Research
Applied Therapeutics stock surges 69% as the FDA says that no advisory committee meeting is required to discuss the govorestat NDA for classic galactosemia.
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
by Zacks Equity Research
The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given indication.
Zoetis Stock Rises 15% in 3 Months: Time to Add to Your Portfolio?
by Zacks Equity Research
ZTS' innovative pet care products, along with efforts to expand the business, are expected to fuel significant growth in the future.
RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises
by Zacks Equity Research
Rocket completes enrollment of patients in a pivotal phase II study evaluating RP-A501 for treating male patients with Danon disease.